Literature DB >> 25722244

Advances in the development of influenza virus vaccines.

Florian Krammer1, Peter Palese2.   

Abstract

Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide. Current influenza virus vaccines are an effective countermeasure against infection but need to be reformulated almost every year owing to antigenic drift. Furthermore, these vaccines do not protect against novel pandemic strains, and the timely production of pandemic vaccines remains problematic because of the limitations of current technology. Several improvements have been made recently to enhance immune protection induced by seasonal and pandemic vaccines, and to speed up production in case of a pandemic. Importantly, vaccine constructs that induce broad or even universal influenza virus protection are currently in preclinical and clinical development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25722244     DOI: 10.1038/nrd4529

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  225 in total

1.  PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

Authors:  J E Salk; H E Pearson; P N Brown; T Francis
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

2.  The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines.

Authors:  Florian Krammer; Rebecca J Cox
Journal:  Expert Rev Vaccines       Date:  2013-10-25       Impact factor: 5.217

3.  Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.

Authors:  B E Johansson; T M Moran; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.

Authors:  Masanori Terajima; John Cruz; Mary Dawn T Co; Jane-Hwei Lee; Kaval Kaur; Jens Wrammert; Patrick C Wilson; Francis A Ennis
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

5.  Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Authors:  Caitlin E Mullarkey; Amy Boyd; Arjan van Laarhoven; Eric A Lefevre; B Veronica Carr; Massimiliano Baratelli; Eleonora Molesti; Nigel J Temperton; Colin Butter; Bryan Charleston; Teresa Lambe; Sarah C Gilbert
Journal:  Eur J Immunol       Date:  2013-06-10       Impact factor: 5.532

6.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

7.  Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Authors:  Richard D Antrobus; Tamara K Berthoud; Caitlin E Mullarkey; Katja Hoschler; Lynda Coughlan; Maria Zambon; Adrian V S Hill; Sarah C Gilbert
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

8.  Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.

Authors:  Teresa Lambe; John B Carey; Yuanyuan Li; Alexandra J Spencer; Arjan van Laarhoven; Caitlin E Mullarkey; Anto Vrdoljak; Anne C Moore; Sarah C Gilbert
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Authors:  Larisa Rudenko; Irina Kiseleva; Anatoly N Naykhin; Marianna Erofeeva; Marina Stukova; Svetlana Donina; Galina Petukhova; Maria Pisareva; Vera Krivitskaya; Michael Grudinin; Zhanna Buzitskaya; Irina Isakova-Sivak; Svetlana Kuznetsova; Natalie Larionova; Julia Desheva; Irina Dubrovina; Alexandra Nikiforova; John C Victor; Kathy Neuzil; Jorge Flores; Vadim Tsvetnitsky; Oleg Kiselev
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

Review 10.  Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Authors:  Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

View more
  260 in total

1.  Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody.

Authors:  Ki Joon Cho; Bert Schepens; Kristof Moonens; Lei Deng; Walter Fiers; Han Remaut; Xavier Saelens
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

3.  Decoding the immune response to successful influenza vaccination.

Authors:  Brian A Kidd
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

4.  Systems vaccinology informs influenza vaccine immunogenicity.

Authors:  Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-03       Impact factor: 11.205

5.  Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.

Authors:  Nicholas C Wu; Andrew J Thompson; Juhye M Lee; Wen Su; Britni M Arlian; Jia Xie; Richard A Lerner; Hui-Ling Yen; Jesse D Bloom; Ian A Wilson
Journal:  Science       Date:  2020-06-19       Impact factor: 47.728

6.  A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors:  Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

Review 7.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

8.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

9.  Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.

Authors:  Peter Pushko; Xiangjie Sun; Irina Tretyakova; Rachmat Hidajat; Joanna A Pulit-Penaloza; Jessica A Belser; Taronna R Maines; Terrence M Tumpey
Journal:  Vaccine       Date:  2016-09-20       Impact factor: 3.641

10.  Mapping a Conformational Epitope of Hemagglutinin A Using Native Mass Spectrometry and Ultraviolet Photodissociation.

Authors:  M Rachel Mehaffey; Jiwon Lee; Jiwon Jung; Michael B Lanzillotti; Edwin E Escobar; Keith R Morgenstern; George Georgiou; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2020-08-12       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.